Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
Open Access
- 4 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (8), 2220-2231
- https://doi.org/10.1038/s41375-020-01089-x
Abstract
This study aimed to identify biomarkers for clinical outcomes in a phase 3 clinical study of blinatumomab or chemotherapy in adults with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Patients were randomized 2:1 to receive blinatumomab, a BiTE® therapy, for 4 weeks (9 μg/day cycle 1 week 1, 28 μg/day thereafter) every 6 weeks, or chemotherapy. Baseline blood samples were evaluated to identify biomarkers prognostic (both treatment groups) or predictive (either treatment groups) for overall survival, event-free survival, hematologic remission, minimal residual disease (MRD) response, duration of response, or adverse events. Baseline values were balanced between treatment groups. Prognostic biomarkers were platelets, tumor burden, and percentage of T cells: each 1-log increase in platelets at baseline was prognostic for improved 6-month survival; lower tumor burden was prognostic for hematologic remission; and a higher percentage of CD3+ T-cells was prognostic for MRD response. Consistent with the BiTE mechanism of action, higher percentage of CD45+ CD3+ CD8+ T cells was associated with hematologic remission following blinatumomab. No examined biomarkers were significant for the risk of grade ≥3 adverse events. Incorporating baseline biomarkers into future studies may help to identify subgroups most likely to benefit from blinatumomab.Keywords
This publication has 22 references indexed in Scilit:
- Blinatumomab: A historical perspectivePharmacology & Therapeutics, 2012
- Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationBlood, 2012
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomabBlood, 2012
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomabExperimental Cell Research, 2011
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeukemia & Lymphoma, 2011
- Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemiaLeukemia & Lymphoma, 2010
- Bispecific T-Cell Engaging Antibodies for Cancer TherapyCancer Research, 2009
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging AntibodyScience, 2008
- Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody constructLeukemia, 2003
- Primary refractory and relapsed adult acute lymphoblastic leukemiaCancer, 1999